Published in Proc Natl Acad Sci U S A on January 09, 2001
The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol (2012) 2.99
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest (2001) 2.05
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther (2005) 1.81
The Survivin saga goes in vivo. J Clin Invest (2001) 1.66
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest (2001) 1.64
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov (2014) 1.61
A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell Int (2010) 1.55
Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line. J Cell Biol (2008) 1.54
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol (2009) 1.39
Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell (2006) 1.33
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Survivin as a preferential target for cancer therapy. Int J Mol Sci (2014) 1.28
Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer (2009) 1.27
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol (2004) 1.13
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest (2002) 1.12
Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets (2008) 1.10
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood (2010) 1.09
Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res (2006) 1.09
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer (2010) 1.03
Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol Biol Cell (2003) 1.02
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res (2006) 1.01
Expression of survivin in human gastric carcinoma and gastric carcinoma model of rats. World J Gastroenterol (2003) 1.00
NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene (2011) 0.97
Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene (2006) 0.95
Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells. Cancer Lett (2011) 0.92
Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant. J Exp Clin Cancer Res (2008) 0.92
Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol (2008) 0.91
Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol (2006) 0.91
A single amino acid change (Asp 53 --> Ala53) converts Survivin from anti-apoptotic to pro-apoptotic. Mol Biol Cell (2003) 0.90
Survivin expression in tuberous sclerosis complex cells. Mol Med (2007) 0.88
Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant. J Exp Clin Cancer Res (2010) 0.88
Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter. Oncotarget (2014) 0.87
Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer (2010) 0.85
Survivin-T34A: molecular mechanism and therapeutic potential. Onco Targets Ther (2010) 0.84
Multi-scale agent-based modeling on melanoma and its related angiogenesis analysis. Theor Biol Med Model (2013) 0.84
Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J Cutan Pathol (2005) 0.82
Nanoformulated cell-penetrating survivin mutant and its dual actions. Int J Nanomedicine (2014) 0.82
Selenium for the prevention of cutaneous melanoma. Nutrients (2013) 0.81
Expression of survivin in primary and metastatic gastric cancer cells obtained by laser capture microdissection. World J Gastroenterol (2004) 0.80
Bioelectric applications for treatment of melanoma. Cancers (Basel) (2010) 0.80
Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol (2010) 0.80
Typical cell signaling response to ionizing radiation: DNA damage and extranuclear damage. Chin J Cancer Res (2012) 0.80
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging. J Biomed Nanotechnol (2015) 0.80
Mitotic slippage and expression of survivin are linked to differential sensitivity of human cancer cell-lines to the Kinesin-5 inhibitor monastrol. PLoS One (2015) 0.79
Amyloid precursor-like protein 2 suppresses irradiation-induced apoptosis in Ewing sarcoma cells and is elevated in immune-evasive Ewing sarcoma cells. Cancer Biol Ther (2013) 0.79
Effect of survivin on tumor growth of colorectal cancer in vivo. Int J Clin Exp Pathol (2015) 0.79
Competitive inhibition of survivin using a cell-permeable recombinant protein induces cancer-specific apoptosis in colon cancer model. Int J Nanomedicine (2015) 0.78
Endothelium derived nitric oxide synthase negatively regulates the PDGF-survivin pathway during flow-dependent vascular remodeling. PLoS One (2012) 0.77
Caspases: enemies within. Science (1998) 19.45
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Analysis of human transcriptomes. Nat Genet (1999) 6.14
Cutaneous melanoma. N Engl J Med (1991) 5.92
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol (1999) 4.11
A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A (1995) 3.80
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
Dysregulation of apoptosis in cancer. J Clin Oncol (1999) 2.98
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res (2000) 2.32
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med (1997) 1.91
Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell (2000) 1.70
Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med (1999) 1.58
bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med (1998) 1.50
Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest (1999) 1.31
Apoptosis and metastasis: increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett (1997) 1.22
c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res (1998) 1.19
Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res (1998) 0.92
Expression and ultrastructural localization of HMB-45 antigen. Br J Dermatol (1996) 0.91
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Biological action of leptin as an angiogenic factor. Science (1998) 6.02
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol (1999) 4.11
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem (2000) 3.30
Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol (1998) 2.64
Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature (2000) 2.55
Transcriptional analysis of human survivin gene expression. Biochem J (1999) 2.39
Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res (1998) 2.38
Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem (1998) 2.27
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell (1993) 2.22
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol (1999) 2.21
Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol (2000) 2.10
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest (2001) 2.05
The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res (1999) 1.89
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87
Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem (1999) 1.82
Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell (2000) 1.70
Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J Clin Invest (2001) 1.64
Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest (1997) 1.61
Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene (2006) 1.59
Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med (1999) 1.58
Cytokine-regulated expression of survivin in myeloid leukemia. Blood (2001) 1.56
Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol (2000) 1.56
Endothelial cell activation by leukocyte microparticles. J Immunol (1998) 1.49
Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res (1999) 1.47
In vivo immunosuppression by targeting a novel protease receptor. Nature (1996) 1.42
Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc Natl Acad Sci U S A (1995) 1.39
Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev (2001) 1.36
Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology (2000) 1.36
Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest (1999) 1.31
Cell division regulation by BIR1, a member of the inhibitor of apoptosis family in yeast. J Biol Chem (2000) 1.29
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol (2001) 1.27
Urine detection of survivin and diagnosis of bladder cancer. JAMA (2001) 1.23
Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem (1997) 1.23
Binding of fibrinogen to human monocytes. J Clin Invest (1986) 1.20
Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol (1997) 1.20
Bacterial flora of the respiratory tract in chronic bronchitis: comparison of transtracheal, fiberbronchoscopic, and oropharyngeal sampling methods. Am Rev Respir Dis (1977) 1.20
A functional analysis of a natural variant of intercellular adhesion molecule-1 (ICAM-1Kilifi). Hum Mol Genet (2000) 1.19
Differential ligand binding specificities of recombinant CD11b/CD18 integrin I-domain. J Biol Chem (1994) 1.18
Survivin does not inhibit caspase-3 activity. Blood (2000) 1.15
Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab Invest (2001) 1.13
Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res (2003) 1.13
Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin. Ann N Y Acad Sci (2001) 1.12
Cytoprotection of human umbilical vein endothelial cells against apoptosis and CTL-mediated lysis provided by caspase-resistant Bcl-2 without alterations in growth or activation responses. J Immunol (2000) 1.08
Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplantation (1999) 1.07
Survivin expression in oral squamous cell carcinoma. Br J Cancer (2003) 1.06
Single unit recordings in the auditory nerve of congenitally deaf white cats: morphological correlates in the cochlea and cochlear nucleus. J Comp Neurol (1998) 1.06
Apical topography and modulation of ICAM-1 expression on activated endothelium. Am J Pathol (1995) 1.05
Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem (1996) 0.99
High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem (1994) 0.97
Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease. Br J Cancer (2011) 0.97
Genetics of the deflagellation pathway in Chlamydomonas. Genetics (1998) 0.96
A peptide derived from the intercellular adhesion molecule-2 regulates the avidity of the leukocyte integrins CD11b/CD18 and CD11c/CD18. J Cell Biol (1995) 0.96
miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene (2011) 0.96
4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol (1997) 0.95
The vascular E-selectin binds to the leukocyte integrins CD11/CD18. Glycobiology (1993) 0.94
Caspase 2-mediated tumor suppression involves survivin gene silencing. Oncogene (2009) 0.94
Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1. J Biol Chem (1997) 0.93
Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol (2001) 0.93
Fa1p is a 171 kDa protein essential for axonemal microtubule severing in Chlamydomonas. J Cell Sci (2000) 0.93
Fibrinogen mediates leukocyte-endothelium bridging in vivo at low shear forces. Blood (1996) 0.93
Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol (2001) 0.93
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene (2009) 0.92
Linear and nonlinear spectral integration in type IV neurons of the dorsal cochlear nucleus. II. Predicting responses with the use of nonlinear models. J Neurophysiol (1997) 0.90
Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology (1998) 0.89
Dual regulation of ligand binding by CD11b I domain. Inhibition of intercellular adhesion and monocyte procoagulant activity by a factor X-derived peptide. J Biol Chem (1998) 0.88
Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation. Biochem J (1996) 0.88
Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A (1998) 0.88
Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol (2001) 0.87
Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem (1996) 0.84
Human T cells infiltrate and injure pig coronary artery grafts with activated but not quiescent endothelium in immunodeficient mouse hosts. Transplantation (2001) 0.84
A distinct tumor suppressor gene locus on chromosome 15q21.1 in sporadic form of colorectal cancer. Cancer Res (2000) 0.83
Cytokinesis, apoptosis and survivin: three for tango? Cell Death Differ (2001) 0.83
Effect of limited nickel availability on methane emission from EDTA treated soils: coenzyme M an alternative biomarker for methanogens. Chemosphere (2012) 0.83
Thromboxane generation by human monocytes enhances platelet function. J Exp Med (1986) 0.81
Topographic mapping of the cutaneous microcirculation using two outputs of laser-Doppler flowmetry: flux and the concentration of moving blood cells. Microvasc Res (1992) 0.80
Diazepam attenuation of restraint stress-induced corticosterone levels is enhanced by prior exposure to repeated restraint. Psychoneuroendocrinology (1997) 0.80
Human TNF can induce nonspecific inflammatory and human immune-mediated microvascular injury of pig skin xenografts in immunodeficient mouse hosts. J Immunol (2000) 0.79
Vascular cell adhesion molecule-1-targeted detection of endothelial activation in human microvasculature. Transplant Proc (2004) 0.78
Allogeneic and xenogeneic vascular injury and protection. Transplant Proc (1998) 0.77
Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. J Biol Chem (1998) 0.77
Contour mapping of the cutaneous microvasculature by computerized laser Doppler velocimetry. J Invest Dermatol (1991) 0.77
Mycosis fungoides palmaris et plantaris or acral pagetoid reticulosis? Am J Dermatopathol (1998) 0.77
AlphaMbeta2 (CD11b/CD18, Mac-1) integrin activation by a unique monoclonal antibody to alphaM I domain that is divalent cation-sensitive. J Leukoc Biol (2000) 0.77
von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol (1986) 0.76
Disparate effects of depletion of CD1d-reactive T cells during early versus late stages of disease in a genetically susceptible model of lupus. Lupus (2011) 0.76
Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus. Clin Exp Immunol (2013) 0.75
High affinity cross-reacting mAb generated by minimal mimicry: implications for the pathogenesis of anti-nuclear autoantibodies and immunosuppression. Proc Natl Acad Sci U S A (1998) 0.75
Judgment error in category vs magnitude scales. Percept Mot Skills (1975) 0.75
Endothelial cell activation by tumor necrosis factor elicits human antiporcine cell-mediated rejection responses. Transplant Proc (2001) 0.75
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Blood (1996) 0.75
A model for partitioning judgment error in psychophysics. Psychol Bull (1970) 0.75